216571-43-6

Basic information

• Product Name: 9-(3,5-di-O-benzoyl-β-L-xylofuranosyl)adenine
• Synonyms: 9-(3,5-di-O-benzoyl-β-L-xylofuranosyl)adenine
• CAS NO: 216571-43-6
• Molecular Weight: 475.461
• Mol File: 216571-43-6.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 9-(3,5-di-O-benzoyl-β-L-xylofuranosyl)adenine(CAS DataBase Reference)
• NIST Chemistry Reference: 9-(3,5-di-O-benzoyl-β-L-xylofuranosyl)adenine(216571-43-6)
• EPA Substance Registry System: 9-(3,5-di-O-benzoyl-β-L-xylofuranosyl)adenine(216571-43-6)

Safety Data

• Hazardous Substances Data: 216571-43-6(Hazardous Substances Data)

Upstream product

• 154463-68-0 9-(2-O-acetyl-3,5-di-O-benzoyl-β-L-xylofuranosyl)adenine 
• 66224-66-6 adenine 
• 201287-82-3 1,2-di-O-acetyl-3,5-di-O-benzoyl-β-L-xylofuranosyle 

Downstream Products

• 216571-44-7 9-(3,5-Di-O-benzoyl-2-deoxy-β-L-threo-pentofuranosyl)adenine 
• 258529-64-5 (2S,3R,5S)-2-[(4-Methoxy-phenyl)-diphenyl-methoxymethyl]-5-(6-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-purin-9-yl)-tetrahydro-furan-3-ol 
• 233681-09-9 (2S,3S,5S)-2-[(4-Methoxy-phenyl)-diphenyl-methoxymethyl]-5-(6-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-purin-9-yl)-tetrahydro-furan-3-ol 
• 233681-07-7 C₄₄H₃₇N₅O₆ 
• 233681-08-8 (2S,3S,5S)-2-Hydroxymethyl-5-(6-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-purin-9-yl)-tetrahydro-furan-3-ol 
• 14365-45-8 L-dA 

Relevant articles and documents

Synthesis and biological evaluation of 9-(β-L-arabinofuranosyl)adenine

For the first time, the stereospecific synthesis of 9-(β-L- arabinofuranosyl) adenine was carded out. Unfortunately, and unlike its 'natural' D-counterpart Vidarabine, this L-enantiomer did not show significant activity when evaluated against a broad rang

β-L-2'-deoxy-nucleosides for the treatment of hepatitis B

This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2''-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2''-deoxy-β-L-erythro-pentofuranonucleoside has the formula: STR1wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2''-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2''-deoxy-β-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.

A new and convenient approach for the synthesis of rffio- and 2′-deoxyrffio-p-l-furanonucleosides starting from β-l-xylofuranonucleosides

Ribo- and 2′-deoxyribo-β-L-ruranosyladenine have been synthesized. Although these compounds have been already reported in the literature, it seemed to us that a more convenient approach for their synthesis deserved to be developed. Intramolecular substitution as well as Mitsunobu reaction were used to invert the configuration of carbon 3′ of starting β-L-xylofuranosyl intermediates. Copyright